Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Karyopharm TherapeuticsKPTI -3.37%40 3-Year EBITDA Growth Rate is 18.70% as of Jun. 2026, which is 65% above its 10-year median of 11.35. GuruFocus rates KPTI with a GF Scoreâ„¢ of 40/100 and a GF Valueâ„¢ of $4.58 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,127 Biotechnology companies, Karyopharm Therapeutics ranks better than 54.48% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Karyopharm Therapeutics was 38.20% per year. The lowest was -32.40% per year. And the median was 11.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Karyopharm Therapeutics 3-Year EBITDA Growth Rate Related Terms
KPTI vs ALGS, EDSA, FLNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.70% mean?
Karyopharm Therapeutics (KPTI) has a 3-Year EBITDA Growth Rate of 18.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Karyopharm Therapeutics and its competitors. This is 65% above median its historical median of 11.35. According to the industry distribution chart, Karyopharm Therapeutics ranks #513 out of 1127 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Karyopharm Therapeutics' 3-Year EBITDA Growth Rate too high?
Karyopharm Therapeutics' current 3-Year EBITDA Growth Rate of 18.70% is 65% above median its 10-year median of 11.35. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Karyopharm Therapeutics' value of 18.70% is 28.1% above this industry median. Based on the distribution chart, Karyopharm Therapeutics ranks #513 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Karyopharm Therapeutics has a GF Scoreâ„¢ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' 3-Year EBITDA Growth Rate compare to ALGS and EDSA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #513 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Karyopharm Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. Karyopharm Therapeutics' value of 18.70% is 28.1% above this benchmark. While the company's 10-year median is 11.35 vs. the industry median of 14.60, Karyopharm Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Karyopharm Therapeutics's current 3-Year EBITDA Growth Rate of 18.70% is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current 3-Year EBITDA Growth Rate is 18.70%, which is 65% above median its own 10-year median of 11.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Possible Value Trap. The stock's GF Value™ is $4.58, compared to a current price of $1.74 — trading 62.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 18.70%, which is 65% above median its 10-year median of 11.35 and 28.1% above the Biotechnology industry median of 14.60. Karyopharm Therapeutics' overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current 3-Year EBITDA Growth Rate is 18.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be undervalued.
The current stock price of $1.74 is trading 62.1% below its estimated GF Value™ of $4.58.
GuruFocus considers Karyopharm Therapeutics to be Possible Value Trap.
Key valuation signals for KPTI:
3-Year EBITDA Growth Rate: 18.70% (65% above median its 10-year median of 11.35)
GF Value™: $4.58 vs. price of $1.74 (62.1% below fair value)
Industry Position: 28.1% above the Biotechnology median (#513 of 1127)
No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
40GF Score
Get the complete analysis for KPTI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KPTI has been successfully added to your 
